ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
3,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
3,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
3,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
3,4,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
3,5,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
4,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
5,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
5,2,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
6,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
6,2,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
6,3,Panic attack,Panic attacks and disorders,Anxiety disorders and symptoms,Psych,N
6,4,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
7,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
8,1,Retinal haemorrhage,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
9,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
9,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
9,3,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
10,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
10,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
11,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
11,2,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
12,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
12,2,Therapy change,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
13,1,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
14,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
14,2,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
14,3,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
15,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
15,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
16,1,Acute abdomen,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
16,2,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
16,3,Colitis ischaemic,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,Y
16,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
16,5,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
16,6,Hypothermia,Body temperature altered,Body temperature conditions,Genrl,N
16,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
17,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
17,2,Cardiorenal syndrome,Heart failures NEC,Heart failures,Card,N
18,1,Headache,Headaches NEC,Headaches,Nerv,N
19,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
19,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
20,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
20,2,Injection site discolouration,Injection site reactions,Administration site reactions,Genrl,N
20,3,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
21,1,Bile duct stenosis,Obstructive bile duct disorders (excl neoplasms),Bile duct disorders,Hepat,N
21,2,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
22,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
22,2,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
22,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
22,4,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
23,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
23,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
24,1,Headache,Headaches NEC,Headaches,Nerv,N
25,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
25,2,Product tampering,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
26,1,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
27,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
28,1,Injection site necrosis,Injection site reactions,Administration site reactions,Genrl,N
28,2,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
29,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
29,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
29,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
30,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
30,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
31,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
31,2,Dry throat,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
31,3,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
31,4,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
31,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
32,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
33,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
34,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
35,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
35,2,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
36,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
36,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
36,3,Pancreatic carcinoma,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,N
37,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
37,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
38,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
38,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
39,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
40,1,Headache,Headaches NEC,Headaches,Nerv,N
41,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
42,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
43,1,Abdominal injury,Abdominal and gastrointestinal injuries NEC,Injuries NEC,Inj&P,N
43,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
43,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
44,1,Retinal detachment,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
45,1,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
46,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
46,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
46,3,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
47,1,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
48,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
48,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
49,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
49,2,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
50,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
51,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
51,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
51,3,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
51,4,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
52,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
53,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
53,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
53,3,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
54,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
54,2,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
55,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
55,2,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
55,3,Wrong technique in device usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
56,1,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
56,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
56,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
56,4,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
56,5,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
57,1,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
57,2,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
57,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
58,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
58,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
58,3,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
58,4,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
59,1,Pancreatic carcinoma,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,N
60,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
60,2,Chronic fatigue syndrome,Asthenic conditions,General system disorders NEC,Genrl,N
60,3,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
60,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
60,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
60,6,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
60,7,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
60,8,Throat irritation,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
61,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
62,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
63,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
64,1,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
65,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
65,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
65,3,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
66,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
66,2,Mucosal disorder,Mucosal findings abnormal,General system disorders NEC,Genrl,N
66,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
66,4,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
67,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
68,1,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
68,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
69,1,Ketosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
70,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
70,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
70,3,Episiotomy,Obstetric therapeutic procedures,Obstetric and gynaecological therapeutic procedures,Surg,N
70,4,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
70,5,Forceps delivery,Obstetric therapeutic procedures,Obstetric and gynaecological therapeutic procedures,Surg,N
71,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
71,2,Facial paralysis,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
71,3,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
71,4,Hypoglycaemia neonatal,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
71,5,Positive airway pressure therapy,Respiratory tract therapeutic procedures NEC,Respiratory tract therapeutic procedures,Surg,N
71,6,Resuscitation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
72,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
73,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
74,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
74,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
75,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
76,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
77,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
77,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
77,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
77,4,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
77,5,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
78,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
78,2,Hyperglycaemic hyperosmolar nonketotic syndrome,Diabetic complications neurological,Diabetic complications,Metab,N
78,3,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
78,4,Urosepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
79,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
80,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
81,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
81,2,Hypoalbuminaemia,Protein metabolism disorders NEC,Protein and amino acid metabolism disorders NEC,Metab,N
81,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
81,4,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
81,5,Kidney infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
82,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
82,2,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
82,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
83,1,Injection site nodule,Injection site reactions,Administration site reactions,Genrl,N
84,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
84,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
85,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
85,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
86,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
87,1,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
88,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
88,2,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
89,1,Headache,Headaches NEC,Headaches,Nerv,N
90,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
90,2,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
91,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
91,2,Gastric haemorrhage,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
92,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
92,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
92,3,Diverticulum,Diverticula,Diverticular disorders,Gastr,N
92,4,Small intestinal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
92,5,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
93,1,Acute cholecystitis necrotic,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
93,2,Biliary sepsis,Hepatobiliary and spleen infections,Infections - pathogen unspecified,Infec,N
93,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
94,1,Acute cholecystitis necrotic,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
94,2,Biliary sepsis,Hepatobiliary and spleen infections,Infections - pathogen unspecified,Infec,N
95,1,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
95,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
95,3,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
96,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
96,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
97,1,Hypercholesterolaemia,Elevated cholesterol,Lipid metabolism disorders,Metab,N
97,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
98,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
98,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
99,1,Nephrotic syndrome,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
100,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
101,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
101,2,Spleen disorder,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
102,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
102,2,Facial pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
102,3,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
102,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
103,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
103,2,Hepatic cirrhosis,Hepatic fibrosis and cirrhosis,Hepatic and hepatobiliary disorders,Hepat,N
104,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
104,2,Groin pain,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
104,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
105,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
106,1,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
106,2,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
107,1,Abdominal transposition,Gastrointestinal tract disorders congenital NEC,Gastrointestinal tract disorders congenital,Cong,N
107,2,Congenital cardiovascular anomaly,Cardiovascular disorders congenital NEC,Cardiac and vascular disorders congenital,Cong,N
108,1,Amputation,Limb therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
109,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
109,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
110,1,Headache,Headaches NEC,Headaches,Nerv,N
111,1,Device delivery system issue,Device issues NEC,Device issues,Prod,N
111,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
111,3,Product label issue,Product label issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
112,1,Headache,Headaches NEC,Headaches,Nerv,N
113,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
113,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
113,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
114,1,Allergic oedema,Allergic conditions NEC,Allergic conditions,Immun,N
114,2,Application site hypersensitivity,Application site reactions,Administration site reactions,Genrl,N
114,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
114,4,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
114,5,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
114,6,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
115,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
115,2,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
115,3,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
115,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
116,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
116,2,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
116,3,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
116,4,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
117,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
117,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
117,3,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
118,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
118,2,Renal cancer,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,Y
119,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
120,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
121,1,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
121,2,Pancreatic pseudocyst,Cystic pancreatic disorders,Exocrine pancreas conditions,Gastr,N
121,3,Pancreatitis acute,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
122,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
123,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
123,2,Lipohypertrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
123,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
123,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
124,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
124,2,Prescribed overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
125,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
126,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
126,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
126,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
126,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
126,5,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
127,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
128,1,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
129,1,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
130,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
131,1,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
131,2,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
131,3,Myalgia,Muscle pains,Muscle disorders,Musc,N
131,4,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
132,1,Bradycardia foetal,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
132,2,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
132,3,Heterotaxia,Congenital disorders NEC,Congenital and hereditary disorders NEC,Cong,N
132,4,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
132,5,Vascular malformation,Vascular anomalies congenital NEC,Cardiac and vascular disorders congenital,Cong,N
133,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
133,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
134,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
134,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
135,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
136,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
136,2,Headache,Headaches NEC,Headaches,Nerv,N
136,3,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
136,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
136,5,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
136,6,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
137,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
138,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
138,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
138,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
139,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
139,2,Delirium,Deliria,Deliria (incl confusion),Psych,N
139,3,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
139,4,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
139,5,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
140,1,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
140,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
141,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
141,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
142,1,Mouth swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
142,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
143,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
143,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
143,3,Hyperemesis gravidarum,Maternal complications of pregnancy NEC,Maternal complications of pregnancy,Preg,N
143,4,Premature delivery,Labour onset and length abnormalities,Maternal complications of labour and delivery,Preg,N
144,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
144,2,Neck injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
145,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
145,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
146,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
146,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
147,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
148,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
149,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
149,2,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
150,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
151,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
152,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
152,2,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
152,3,Product colour issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
152,4,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
153,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
153,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
154,1,Retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
155,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
155,2,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
156,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
157,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
157,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
157,3,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
158,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
159,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
160,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
161,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
161,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
161,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
162,1,Product colour issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
162,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
163,1,Headache,Headaches NEC,Headaches,Nerv,N
164,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
164,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
164,3,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
164,4,Metabolic acidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
164,5,Supraventricular tachycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
165,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
165,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
165,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
165,4,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
166,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
167,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
167,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
167,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
168,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
168,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
168,3,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
168,4,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
168,5,Foetal damage,Foetal complications NEC,Foetal complications,Preg,N
168,6,Large for dates baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
168,7,Recalled product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
169,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
169,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
169,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
170,1,Pancreatitis acute,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
171,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,Y
171,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
172,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
173,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
173,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
174,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
174,2,Cognitive disorder,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
174,3,Retrograde amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
175,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
175,2,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
175,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
175,4,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
175,5,Suspected product tampering,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
176,1,Completed suicide,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,Y
176,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
177,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
177,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
177,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
177,4,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
178,1,Hepatic cancer,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
179,1,Accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,Y
180,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
181,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
181,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
182,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
183,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
184,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
184,2,Skin atrophy,Skin hypoplasias and atrophies,Cornification and dystrophic skin disorders,Skin,N
185,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
186,1,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
187,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
187,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
188,1,Hypoaesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
188,2,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
188,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
189,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
190,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
190,2,Crohn's disease,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
190,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
190,4,Frequent bowel movements,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
190,5,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
191,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
191,2,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
191,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
192,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
193,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
193,2,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
193,3,Brain fog,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
193,4,Breath odour,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
193,5,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
193,6,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
193,7,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
193,8,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
193,9,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
193,10,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
193,11,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
193,12,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
193,13,Food intolerance,Food malabsorption and intolerance syndromes (excl sugar intolerance),Food intolerance syndromes,Metab,N
193,14,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
193,15,Irritable bowel syndrome,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
193,16,Nasal congestion,Nasal congestion and inflammations,Upper respiratory tract disorders (excl infections),Resp,N
193,17,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
193,18,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
194,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
195,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
195,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
196,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
196,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
197,1,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
198,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
198,2,Non-alcoholic steatohepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
199,1,Lichen sclerosus,Papulosquamous conditions,Epidermal and dermal conditions,Skin,N
199,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
199,3,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
199,4,Skin tightness,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
200,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
201,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
201,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
201,3,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
202,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
202,2,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
202,3,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
202,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
203,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
204,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
205,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
205,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
205,3,Guillain-Barre syndrome,Acute polyneuropathies,Peripheral neuropathies,Nerv,N
205,4,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
205,5,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
205,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
206,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
206,2,Guillain-Barre syndrome,Acute polyneuropathies,Peripheral neuropathies,Nerv,N
206,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
207,1,Diabetic foot,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
207,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
207,3,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
208,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
208,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
209,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
209,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
210,1,Device defective,Device physical property and chemical issues,Device issues,Prod,N
210,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
210,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
211,1,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
212,1,Hepatic enzyme increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
212,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
213,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
213,2,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
213,3,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
214,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
215,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
215,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
215,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
215,4,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
216,1,Headache,Headaches NEC,Headaches,Nerv,N
216,2,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
216,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
216,4,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
217,1,Device information output issue,Device information output issues,Device issues,Prod,N
217,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
217,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
217,4,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
217,5,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
217,6,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
218,1,Device failure,Device issues NEC,Device issues,Prod,N
218,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
219,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
219,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
220,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
221,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
222,1,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
223,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
224,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
224,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
224,3,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
224,4,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
225,1,Lip and/or oral cavity cancer,Lip and oral cavity neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
225,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
226,1,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
227,1,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
228,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
228,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
229,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
229,2,Troponin increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
229,3,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
230,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
230,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
231,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
232,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
232,2,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
233,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
233,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
234,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
234,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
234,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
235,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
236,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
237,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
238,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
238,2,Coronavirus test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
238,3,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
238,4,Vascular stent thrombosis,Vascular complications associated with device,Complications associated with device,Genrl,N
239,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
239,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
240,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
240,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
240,3,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
240,4,Plasma cell myeloma,Plasma cell myelomas,Plasma cell neoplasms,Neopl,N
241,1,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
242,1,Uterine cancer,Uterine neoplasms malignant NEC,Reproductive neoplasms female malignant and unspecified,Neopl,N
243,1,Prostatic abscess,Male reproductive tract infections,Infections - pathogen unspecified,Infec,N
244,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
244,2,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
244,3,Vascular rupture,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
245,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
245,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
246,1,Device defective,Device physical property and chemical issues,Device issues,Prod,N
246,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
247,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
247,2,Pancreatitis acute,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
248,1,Cataract operation,Lens therapeutic procedures,Eye therapeutic procedures,Surg,N
249,1,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
249,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
250,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
250,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
250,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
251,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
252,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
252,2,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
252,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
253,1,Transcatheter aortic valve implantation,Cardiac valve therapeutic procedures,Cardiac therapeutic procedures,Surg,N
254,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
254,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
254,3,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
254,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
254,5,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
254,6,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
254,7,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
254,8,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
254,9,Red blood cell sedimentation rate increased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
254,10,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
255,1,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
256,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
256,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
256,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
257,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
257,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
258,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
258,2,Bladder obstruction,Bladder disorders NEC,Bladder and bladder neck disorders (excl calculi),Renal,N
258,3,Hydronephrosis,Renal obstructive disorders,Renal disorders (excl nephropathies),Renal,N
258,4,Hydroureter,Ureteric disorders NEC,Ureteric disorders,Renal,N
258,5,Nephrolithiasis,Renal lithiasis,Urolithiases,Renal,N
259,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
259,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
260,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
261,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
261,2,Device information output issue,Device information output issues,Device issues,Prod,N
261,3,Device power source issue,Device malfunction events NEC,Device issues,Prod,N
261,4,Expired device used,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
261,5,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
261,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
262,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
263,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
263,2,Device failure,Device issues NEC,Device issues,Prod,N
264,1,Device defective,Device physical property and chemical issues,Device issues,Prod,N
264,2,Device delivery system issue,Device issues NEC,Device issues,Prod,N
264,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
264,4,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
265,1,Circumoral swelling,Angioedemas,Angioedema and urticaria,Skin,N
265,2,Ear swelling,Ear disorders NEC,Aural disorders NEC,Ear,N
265,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
265,4,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
266,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
267,1,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
268,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
268,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
269,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
269,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
270,1,Device defective,Device physical property and chemical issues,Device issues,Prod,N
270,2,Device failure,Device issues NEC,Device issues,Prod,N
270,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
270,4,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
270,5,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
270,6,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
271,1,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
271,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
272,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
272,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
272,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
272,4,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
273,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
273,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
274,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
274,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
275,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
275,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
276,1,Disorientation,Confusion and disorientation,Deliria (incl confusion),Psych,N
276,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
276,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
276,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
277,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
278,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
279,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
280,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
280,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
281,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
281,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
282,1,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
283,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
284,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
284,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
284,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
284,4,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
285,1,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
286,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
287,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
288,1,Osteogenesis imperfecta,Non-site specific bone disorders congenital,Musculoskeletal and connective tissue disorders congenital,Cong,N
288,2,Rib fracture,Thoracic cage fractures and dislocations,Bone and joint injuries,Inj&P,N
289,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
290,1,Supraventricular tachycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
291,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
291,2,Drug delivery system issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
292,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
292,2,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
292,3,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
292,4,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
292,5,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
292,6,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
292,7,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
292,8,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
292,9,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
292,10,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
292,11,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
292,12,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
292,13,Headache,Headaches NEC,Headaches,Nerv,N
292,14,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
292,15,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
292,16,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
292,17,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
292,18,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
293,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
294,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
294,2,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
295,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
296,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
297,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
298,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
299,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
300,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
301,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
301,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
301,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
302,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
303,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
304,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
304,2,Device mechanical issue,Device physical property and chemical issues,Device issues,Prod,N
305,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
306,1,Headache,Headaches NEC,Headaches,Nerv,N
307,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
307,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
308,1,Rash morbilliform,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
309,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
310,1,Mouth swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
311,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
312,1,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
313,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
314,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
314,2,Device failure,Device issues NEC,Device issues,Prod,N
314,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
315,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
315,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
316,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
317,1,SARS-CoV-2 test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
318,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
319,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
319,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
319,3,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
319,4,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
319,5,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
319,6,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
320,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
320,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
321,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
321,2,Prescription drug used without a prescription,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
321,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
322,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
322,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
322,3,Product temperature excursion issue,Product distribution and storage issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
323,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
323,2,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
324,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
324,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
324,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
324,4,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
324,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
324,6,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
325,1,Limb mass,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
325,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
326,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
326,2,Device failure,Device issues NEC,Device issues,Prod,N
326,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
327,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
327,2,Device leakage,Device issues NEC,Device issues,Prod,N
327,3,Drug delivery system issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
327,4,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
327,5,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
327,6,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
328,1,Deafness,Hearing losses,Hearing disorders,Ear,N
328,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
328,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
329,1,Feeding disorder,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
329,2,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
329,3,Headache,Headaches NEC,Headaches,Nerv,N
329,4,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
329,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
329,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
330,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
331,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
331,2,Product appearance confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
331,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
332,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
332,2,Device defective,Device physical property and chemical issues,Device issues,Prod,N
332,3,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
333,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
333,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
334,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
335,1,Pancreatic disorder,Pancreatic disorders NEC,Exocrine pancreas conditions,Gastr,N
336,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
336,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
336,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
337,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
337,2,Device failure,Device issues NEC,Device issues,Prod,N
338,1,Device delivery system issue,Device issues NEC,Device issues,Prod,N
338,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
339,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
339,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
339,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
340,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
340,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
340,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
340,4,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
340,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
341,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
341,2,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
342,1,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
342,2,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
343,1,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
344,1,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
344,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
344,3,Multiple use of single-use product,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
344,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
344,5,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
344,6,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
345,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
346,1,Coma,Coma states,Neurological disorders NEC,Nerv,N
347,1,Skin weeping,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
348,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
348,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
349,1,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
349,2,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
350,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
350,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
351,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
351,2,Device defective,Device physical property and chemical issues,Device issues,Prod,N
351,3,Device delivery system issue,Device issues NEC,Device issues,Prod,N
352,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
352,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
352,3,Headache,Headaches NEC,Headaches,Nerv,N
352,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
352,5,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
353,1,Pemphigoid,Bullous conditions,Epidermal and dermal conditions,Skin,N
354,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
354,2,Device wireless communication issue,Device issues NEC,Device issues,Prod,N
355,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
355,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
356,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
356,2,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
357,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
357,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
358,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
358,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
359,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
360,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
361,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
362,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
363,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
364,1,Brain injury,Structural brain disorders NEC,Structural brain disorders,Nerv,N
364,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
365,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
365,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
366,1,Glossodynia,Tongue signs and symptoms,Tongue conditions,Gastr,N
366,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
366,3,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
366,4,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
366,5,Tongue erythema,Tongue signs and symptoms,Tongue conditions,Gastr,N
367,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
367,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
368,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
368,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
368,3,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
368,4,Ketosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
368,5,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
369,1,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
369,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
369,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
369,4,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
369,5,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
370,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
371,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
372,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
372,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
373,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
373,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
373,3,Product dose omission in error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
374,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
375,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
375,2,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
376,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
376,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
377,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
377,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
377,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
377,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
377,5,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
378,1,Chronic sinusitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
378,2,Feeding disorder,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
378,3,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
378,4,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
378,5,Nasal oedema,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
378,6,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
379,1,Device delivery system issue,Device issues NEC,Device issues,Prod,N
379,2,Device wireless communication issue,Device issues NEC,Device issues,Prod,N
379,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
379,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
380,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
381,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
381,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
382,1,Device wireless communication issue,Device issues NEC,Device issues,Prod,N
382,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
383,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
384,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
384,2,Device wireless communication issue,Device issues NEC,Device issues,Prod,N
385,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
386,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
386,2,Device mechanical issue,Device physical property and chemical issues,Device issues,Prod,N
387,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
388,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
388,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
388,3,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
388,4,Device data issue,Device issues NEC,Device issues,Prod,N
388,5,Drug delivery system malfunction,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
388,6,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
389,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
389,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
390,1,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
391,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
392,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
392,2,Device delivery system issue,Device issues NEC,Device issues,Prod,N
392,3,Device information output issue,Device information output issues,Device issues,Prod,N
393,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
393,2,Product availability issue,Product supply and availability issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
394,1,Haematological infection,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
394,2,Hepatic infection,Hepatobiliary and spleen infections,Infections - pathogen unspecified,Infec,N
394,3,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
395,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
395,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
396,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
396,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
397,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
397,2,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
398,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
398,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
399,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
399,2,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
400,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
401,1,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
402,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
402,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
402,3,Physical product label issue,Product label issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
402,4,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
403,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
404,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
405,1,Ketosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
406,1,Ketosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
407,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
407,2,Product availability issue,Product supply and availability issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
407,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
408,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
409,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
410,1,Device information output issue,Device information output issues,Device issues,Prod,N
410,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
411,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
411,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
412,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
412,2,Device issue,Device issues NEC,Device issues,Prod,N
413,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
413,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
414,1,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
415,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
415,2,Device delivery system issue,Device issues NEC,Device issues,Prod,N
415,3,Device mechanical issue,Device physical property and chemical issues,Device issues,Prod,N
416,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
416,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
417,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
418,1,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
418,2,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
419,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
419,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
420,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
420,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
421,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
422,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
422,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
423,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
423,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
424,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
425,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
426,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
427,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
427,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
427,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
428,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
428,2,Intentional dose omission,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
429,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
429,2,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
430,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
431,1,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
431,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
431,3,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
432,1,Device delivery system issue,Device issues NEC,Device issues,Prod,N
432,2,Device issue,Device issues NEC,Device issues,Prod,N
432,3,Device leakage,Device issues NEC,Device issues,Prod,N
432,4,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
432,5,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
433,1,Injection site discharge,Injection site reactions,Administration site reactions,Genrl,N
433,2,Product odour abnormal,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
433,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
433,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
434,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
434,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
435,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
435,2,Influenza,Influenza viral infections,Viral infectious disorders,Infec,N
435,3,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
436,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
437,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
437,2,Product administered at inappropriate site,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
438,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
439,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
439,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
439,3,Device failure,Device issues NEC,Device issues,Prod,N
439,4,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
439,5,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
439,6,Intentional self-injury,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
439,7,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
439,8,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
440,1,Device issue,Device issues NEC,Device issues,Prod,N
440,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
440,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
